Open AccessSingle-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection WithVibrio choleraeO1 El Tor
Author(s) -
Wilbur H. Chen,
Mitchell B. Cohen,
Beth D. Kirkpatrick,
Rebecca C. Brady,
David Galloway,
Marc Gurwith,
R. H. Hall,
Robert A. Kessler,
Michael Lock,
Douglas J. Haney,
Caroline E. Lyon,
Marcela F. Pasetti,
Jakub K. Simon,
Flóra K. Szabó,
Sharon M. Tennant,
Myron M. Levine
Publication year - 2016
Publication title -
clinical infectious diseases
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciw145
Subject(s) - cholera , medicine , vibrio cholerae , cholera vaccine , seroconversion , placebo , vaccination , el tor , virology , adverse effect , microbiology and biotechnology , immunology , antibody , biology , bacteria , genetics , alternative medicine , pathology
No licensed cholera vaccine is presently available in the United States. Cholera vaccines available in other countries require 2 spaced doses. A single-dose cholera vaccine that can rapidly protect short-notice travelers to high-risk areas and help control explosive outbreaks where logistics render 2-dose immunization regimens impractical would be a major advance.PXVX0200, based on live attenuated Vibrio cholerae O1 classical Inaba vaccine strain CVD 103-HgR, elicits seroconversion of vibriocidal antibodies (a correlate of protection) within 10 days of a single oral dose. We investigated the protection conferred by this vaccine in a human cholera challenge model.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom